321 related articles for article (PubMed ID: 33181636)
1. Hyperprogression on immunotherapy with complete response to chemotherapy in a NSCLC patient with high PD-L1 and STK11: A case report.
Fricke J; Mambetsariev I; Pharaon R; Subbiah S; Rajurkar S; Salgia R
Medicine (Baltimore); 2020 Nov; 99(46):e22323. PubMed ID: 33181636
[TBL] [Abstract][Full Text] [Related]
2. Pulmonary large cell carcinoma, highly positive for PD-L1, shows marked response to pembrolizumab: A case report.
Okabe N; Mine H; Takagi H; Watanabe M; Muto S; Matsumura Y; Shio Y; Suzuki H
Thorac Cancer; 2021 Apr; 12(7):1141-1144. PubMed ID: 33605014
[TBL] [Abstract][Full Text] [Related]
3. Hyperprogressive disease under anti-PD-1 rechallenge after initial response to anti-PD-1 treatment for non-small cell lung cancer: a case report.
Xu S; Shukuya T; Shimamura S; Hayashi T; Sato Y; Shiozaki H; Nishioki T; Nishino K; Kato M; Hattori A; Shimada N; Suzuki K; Kitano S; Takahashi K
Transl Lung Cancer Res; 2024 Mar; 13(3):666-672. PubMed ID: 38601437
[TBL] [Abstract][Full Text] [Related]
4. Case Report: Tumor Microenvironment Characteristics in a Patient With HER2 Mutant Lung Squamous Cell Carcinoma Harboring High PD-L1 Expression Who Presented Hyperprogressive Disease.
Xia L; Yu Y; Lan F; Yan J; Li J; Li W; Xia Y
Front Oncol; 2021; 11():760703. PubMed ID: 35004282
[TBL] [Abstract][Full Text] [Related]
5. Hyperprogression: A Unique Phenomenon of Progression of Existing Tumor Secondary to Immunotherapy.
Mandal S; Ray B; Baniya Sharma S; Poulose J; Kasireddy V
Cureus; 2021 Sep; 13(9):e17992. PubMed ID: 34667669
[TBL] [Abstract][Full Text] [Related]
6. Placental and Breast Metastasis of Squamous Cell Carcinoma in a Patient With Recurrent Respiratory Papillomatosis.
Gogineni V; Gingell L; Varghese M; Hrinczenko B
Cureus; 2023 Sep; 15(9):e46183. PubMed ID: 37905287
[TBL] [Abstract][Full Text] [Related]
7. Renal Immune-related Adverse Event of Pembrolizumab Masked by Pemetrexed.
Nagase K; Murai Y; Yokoyama-Kokuryo W; Nagasaka T; Sato Y; Watanabe T; Ito Y; Nagase F; Fujita Y
Intern Med; 2024 Jan; 63(2):265-270. PubMed ID: 37258166
[TBL] [Abstract][Full Text] [Related]
8. Favorable outcome of a histiocytic sarcoma patient treated with immune checkpoint inhibitor: a case report.
Nguyen LT; Pham GH; Vu PT; Yi HG
Ann Med Surg (Lond); 2023 Dec; 85(12):6274-6278. PubMed ID: 38098600
[TBL] [Abstract][Full Text] [Related]
9. Leveraging Transcriptomics Data to Refine Immunotherapy Response Prediction in NSCLC: STK11 Deficiency and Beyond.
Amori G; Sugawara E; Inamura K
J Thorac Oncol; 2023 Nov; 18(11):e134-e135. PubMed ID: 37879772
[No Abstract] [Full Text] [Related]
10. [Adenocarcinoma with Aplastic Anemia as an Immune-related Adverse Event Caused by Pembrolizumab: Report of a Case].
Hashimoto S; Haga N; Morimoto M; Doi Y
Kyobu Geka; 2024 Mar; 77(3):235-238. PubMed ID: 38465499
[TBL] [Abstract][Full Text] [Related]
11. Association of Programmed Cell Death 1 Inhibitor with Circumorificial Plasmacytosis.
Tanimu Y; Coombs R; Tanimu S; Onitilo A
Case Rep Oncol; 2024; 17(1):33-38. PubMed ID: 38188483
[TBL] [Abstract][Full Text] [Related]
12. A Remarkable Clinical Response to Pembrolizumab in a Rare Spindle Cell Carcinoma of the Lung.
Tsurumi K; Kawashima Y; Akahira J; Saito R; Toi Y; Nakamura A; Yamanda S; Kimura Y; Honda Y; Sugawara S
JMA J; 2020 Jan; 3(1):83-86. PubMed ID: 33324781
[TBL] [Abstract][Full Text] [Related]
13. Hyperprogression Under Immune Checkpoint-Based Immunotherapy-Current Understanding, The Role of PD-1/PD-L1 Tumour-Intrinsic Signalling, Future Directions and a Potential Large Animal Model.
Kocikowski M; Dziubek K; Parys M
Cancers (Basel); 2020 Mar; 12(4):. PubMed ID: 32230745
[TBL] [Abstract][Full Text] [Related]
14. Hyperprogression: A novel response pattern under immunotherapy.
Han XJ; Alu A; Xiao YN; Wei YQ; Wei XW
Clin Transl Med; 2020 Sep; 10(5):e167. PubMed ID: 32997401
[TBL] [Abstract][Full Text] [Related]
15. Intrapleural perfusion hyperthermia improves the efficiency of anti‑PD1 antibody‑based therapy for lung adenocarcinoma: A case report.
Wang X; Song J; Hu L; Ren G; Geng N; Song Z
Oncol Lett; 2024 May; 27(5):217. PubMed ID: 38586203
[TBL] [Abstract][Full Text] [Related]
16. Cytokine Release Syndrome More than Two Years after Pembrolizumab Introduction: A Case Report.
Nakashima K; Kitani K; Kono K; Yoshihara K; Kawakado K; Kobayashi M; Okuno T; Amano Y; Tsubata Y; Isobe T
Intern Med; 2023 Dec; ():. PubMed ID: 38104995
[TBL] [Abstract][Full Text] [Related]
17. Letter re: Hyperprogressive disease during PD-1 blockade in patients with advanced gastric cancer.
Aix Ponce S; Cousin S; Dubos P; Belcaid L; Bayle A; Italiano A
Eur J Cancer; 2023 Nov; 193():113309. PubMed ID: 37776631
[No Abstract] [Full Text] [Related]
18. Hyperprogressive disease: a distinct effect of immunotherapy?
Popat V; Gerber DE
J Thorac Dis; 2019 Mar; 11(Suppl 3):S262-S265. PubMed ID: 30997192
[No Abstract] [Full Text] [Related]
19. Randomized clinical trial of pembrolizumab vs chemotherapy for previously untreated Chinese patients with PD-L1-positive locally advanced or metastatic non-small-cell lung cancer: KEYNOTE-042 China Study.
Wu YL; Zhang L; Fan Y; Zhou J; Zhang L; Zhou Q; Li W; Hu C; Chen G; Zhang X; Zhou C; Dang T; Sadowski S; Kush DA; Zhou Y; Li B; Mok T
Int J Cancer; 2021 May; 148(9):2313-2320. PubMed ID: 33231285
[TBL] [Abstract][Full Text] [Related]
20. Identification of an Immune-Related Prognostic Predictor in Hepatocellular Carcinoma.
Wu L; Quan W; Luo Q; Pan Y; Peng D; Zhang G
Front Mol Biosci; 2020; 7():567950. PubMed ID: 33195412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
